Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | CDK1 | P06493 | 7/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314755 | 0.86 | JAK2 (0.44) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL3586281 | 0.82 | LMNA (0.55) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL13314752 | 0.77 | KMT2A (0.41) | KMT2ACDK2CLK4CLK2MAPK9 | |
| SCHEMBL3580999 | 0.77 | CDK2 (0.46) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL14511661 | 0.76 | JAK2 (0.45) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL1646344 | 0.76 | MAPT (0.46) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL13314759 | 0.75 | MCL1 (0.54) | HTTMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL13314754 | 0.75 | L3MBTL1 (0.51) | HTTMEN1KMT2APOLB | |
| SCHEMBL3591831 | 0.75 | MEN1 (0.42) | LMNAJAK2JAK1TYK2HTT | |
| SCHEMBL3584925 | 0.75 | NPC1 (0.51) | JAK2JAK1TYK2HTTNOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | LMNA 1071/4885JAK2 734/4885JAK1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.